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The inhibitor of apoptosis protein, XIAP, is frequently overexpressed in chemoresistant human tumours. An antisense
oligonucleotide (AEG 35156/GEM 640) that targets XIAP has recently entered phase I trials in the UK. Method validation data
are presented on three pharmacodynamic assays that will be utilised during this trial. Quantitative RT-PCR was based on a Taqman
assay and was confirmed to be specific for XIAP. Assay linearity extended over four orders of magnitude. MDA-MB-231/U6-E1 cells
and clone X-G4 stably expressing an RNAi vector against XIAP were chosen as high and low XIAP expression quality controls
(QCs). Within-day and between-day coefficients of variation (CVs) in precision for cycle threshold (CT) and delta CT values
(employing GAPDH and beta 2 microglobulin as housekeepers) were always less than 10%. A Western blotting technique was
validated using a GST–XIAP fusion protein as a standard and HeLa cells and SF268 (human glioblastoma) cells as high and low XIAP
expression QCs. Specificity of the final choice of antibody for XIAP was evaluated by analysing a panel of cell lines including clone
X-G4. The assay was linear over a 29-fold range of protein concentration and between-day precision was 29% for the low QC and
23% for the high QC when normalised to GAPDH. XIAP protein was also shown to be stable at  801C for at least 60 days. M30-
Apoptosenset plasma Elisa detects a caspase-cleaved fragment of cytokeratin 18 (CK18), believed to be a surrogate marker for
tumour cell apoptosis. Generation of an independent QC was achieved through the treatment of X-G4 cells with staurosporine and
collection of media. Measurements on assay precision and kit-to-kit QC were always less than 10%. The M30 antigen (CK18-Asp
396)
was stable for 3 months at  801C, while at 371C it had a half-life of 80–100h in healthy volunteer plasma. Results from the phase I
trial are eagerly awaited.
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The X-linked inhibitor of apoptosis, XIAP, is a member of a large
family of proteins which share in common one or more structural
motifs known as BIR domains (LaCasse et al, 1998; Liston et al,
2003). IAPs function to block cell death by binding to and
inhibiting the action of caspases involved in the execution phase of
apoptosis (Holcik and Korneluk, 2001; Holcik et al, 2001). XIAP is
the most potent endogenous caspase inhibitor (Stennicke et al,
2002) and its overexpression results in a blockade of cell death
arising from a number of different triggers including cytotoxic
drugs, ionising radiation and growth factor deprivation (Holcik
and Korneluk, 2001; Holcik et al, 2001). Thus, it can antagonise
both the mitochondrial regulated (intrinsic) and death-receptor-
mediated (extrinsic) apoptotic pathways (Hengartner, 2000). In
clinical investigations, the protein has been shown to be over-
expressed in a number of different tumours relative to normal
tissue (Hofmann et al, 2002; Krajewska et al, 2003; Shiraki et al,
2003) and high expression is often associated with poor patient
outcome (Tamm et al, 2000, 2004; Ramp et al, 2004; Yan et al,
2004) and resistance to chemotherapy (Parton et al, 2002).
Studies with knockout mice have shown that the absence of
XIAP does not adversely affect the development of normal tissues
(Harlin et al, 2001), whereas antisense knockdown (KD) of the
protein in a non-small-cell lung cancer (NSCLC) xenograft (H460)
produces significant antitumour activity (Hu et al, 2003).
Furthermore, small-molecule derivatives of polyphenylurea,
screened for efficacy in overcoming XIAP inhibition of caspase
3, have demonstrated in vivo antitumour activity against human
prostate and colon cancer xenografts in the absence of significant
toxicity to normal tissues (Schimmer et al, 2004). Thus, XIAP may
represent a novel and tumour-selective therapeutic target for
anticancer drug design (Huang et al, 2004).
Recently, a second-generation 19-mer antisense chimeric
oligonucleotide targeting XIAP, constructed as a mixed backbone
of chemically modified DNA/RNA nucleotides (denoted AEG
35156/GEM 640), has entered Phase I clinical evaluation at two
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sdifferent centres in the United Kingdom. An integral component
of this clinical trial will be that pharmacodynamic (PD) studies
are performed on patient-derived samples (plasma, peripheral
blood mononuclear cells and tumour biopsies) in order to
provide evidence of target KD. Laboratory studies that support
clinical trials are being subjected increasingly to more stringent
regulatory requirements, especially with the publication of the
European Directive on Clinical Trials (Fontaine and Rosengren,
2001) as a Statutory Instrument (1031, HMSO) in the UK from
May 2004. This paper describes the validation of three of the
assays that will be employed during the phase I trial of AEG 35156/
GEM 640.
MATERIALS AND METHODS
Reagents
Staurosporine was from the Sigma Chemical Company (Poole,
England) and caspase inhibitor I (z-VAD) was from Calbiochem
(Darmstadt, Germany). Custom-synthesised PCR primers for XIAP
and RNase-free DNase were from Qiagen (Valencia, CA, USA). An
XIAP-specific Taqman probe was obtained from IDT Inc.
(Coralville, IO, USA). Taqman EZ reverse transcriptase (RT)–
PCR core reagents kit, PCR primer pairs and gene-specific Taqman
reagents for GADPH, cyclophilin A, beta 2 microglobulin, 18S
rRNA and Tata-binding protein were all from Applied Biosystems
Inc. (ABI, Foster City, CA, USA). GST–XIAP fusion protein was
either produced in house (Aegera) or obtained from Alexis
(ALEXIS Corporation LTD, Nottingham, UK). Monoclonal anti-
bodies to XIAP were obtained as follows: hILP/XIAP clones 28 and
48 were from BD Biosciences (Pharmingen, San Diego, CA, USA)
and anti-XIAP clone 2F1 was from MBL (Watertown, MA, USA).
Anti-GAPDH monoclonal antibody (clone 6C5) was from Ad-
vanced ImmunoChemical Inc. (Long Beach, CA, USA). Goat anti-
mouse secondary antibody was from Amersham (Arlington
Heights, IL, USA) and geneticin was from Invitrogen Gibco BRL
(Carlsbad, CA, USA). BSA protein standard was from Pierce
(Rockford, IL, USA). M30-Apoptosenset 96-well kits for the
determination of cleaved cytokeratin (CK) 18 were from PEVIVA
(Bromma, Sweden). All other reagents and chemicals were of the
highest grade available commercially. Water was purified and
deionised in a Millipore Elix 3 system (Millipore, Watford,
England).
Cell lines
MDA-MB-231/X-G4 human breast cancer cells stably transfected
with a vector containing an siRNA to XIAP and parental MDA-
MB-231/U6-E1 cells stably transfected with only the U6 promoter
were generated in house (McManus et al, 2004). HeLa human
cervical cancer cells were from the American Type Culture
Collection (Manassas, VA, USA) and SF268 human glioblastoma
cells were from the University of California in San Francisco Brain
Tumour Bank (San Francisco, CA, USA). Cell lines were cultured
in RPMI 1640 medium (BE12-167F, Cambrex Bio Science, Verviers,
Belgium) containing 1% glutamine, and 10% foetal bovine serum
(Harlan Sera-Lab, Loughborough, England) at 371C in a humidi-
fied atmosphere of 5% CO2 in air. In the case of the X-G4 clone and
parental U6-E1 cells, geneticin (G1397, Sigma) at a concentration
of 300mgml
 1 was supplemented to media to maintain selection of
transfected cells.
Preparation of cancer cell pellets as quality control (QC)
samples for both quantitative (q)RT-PCR and Western
blotting
In order to act as QC samples and a surrogate matrix for tumour
tissue, cancer cell lines were prepared as solid pellets from a stock
culture and aliquoted into individual tubes according to the
following procedure. Cells were grown to near confluence, then the
medium was aspirated. The cell monolayers were washed twice
with phosphate-buffered saline (PBS), pH 7.4, and detached
according to a standard trypsinisation protocol. A volume of 5–
10ml of media was added and each cell suspension was transferred
to a universal screw top container and centrifuged at 300g for
5min. The supernatants were discarded, the cell pellets resus-
pended in 20ml of ice-cold PBS and centrifuged at 300g for 5min.
Finally, the supernatants were discarded and the pellets stored at
 801C prior to analysis by qRT-PCR or Western blot analysis
(WBA).
XIAP qRT-PCR assay method
qRT-PCR was performed essentially as described in detail (Fong
et al, 2000; McKinnon et al, 2002; Hu et al, 2003). In brief, after cell
lysis RNA was extracted from cell pellets using the RNeasy mini kit
(Qiagen) and then treated with RNase-free DNase. A pCI-plasmid
containing XIAP cDNA, which was employed as a standard, was
purified from transformed Escherichia coli using the HiSpeed
plasmid maxi kit (Qiagen). Quantitation of extracted RNA and
evaluation of purity was performed by UV spectrophotometry at
260nm and by measuring absorbance ratios at 260 vs 280nm. The
quantity and quality of purified DNA were verified by spectro-
photometry, as well as by agarose gel electrophoresis and ethidium
bromide staining. For each cell line, 25ng of total RNA was
employed and was reverse-transcribed and PCR amplified utilising
the Taqman EZ RT–PCR kit (ABI). XIAP primers and probes were
used at concentrations of 600 and 200nM, respectively. The
thermal cycling conditions for the RT step were as follows: 501C
for 2min, 601C for 30min and 951C for 5min, then followed by 45
cycles of PCR at 941C for 20s and 601C for 1min per cycle. All the
RT–PCR steps were performed using an ABI Prism 7700 Sequence
Detector (ABI), and quantitated using the cycle threshold (CT)
method. XIAP RNA levels were also normalised to two house-
keeping genes (delta CT method), and were also occasionally
compared to another QC sample acting as a reference point
(delta–delta CT).
Western blot analysis of XIAP
Western blotting of cancer cell pellets was conducted essentially as
described previously in detail (Hu et al, 2003). Pellets were
homogenised in ice-cold lysis buffer consisting of 50mM Tris–
HCL, pH 7, 150mM NaCl, 1mM EDTA, 1mM sodium fluoride, 1mM
vanadate, 1% (vv
 1) Nonidet P-40 and 0.25% sodium deoxycho-
late in a cocktail of protease inhibitors (leupeptin, aprotinin and
PMSF). Protein content of cell lysates was determined by the Bio-
Rad assay, standardised with bovine serum albumin (Bio-Rad
Laboratories, Hercules, CA, USA). Equal amounts of protein
(10mglane
 1) were subjected to electrophoresis and separated on
12 or 4–15% gradient SDS–polyacrylamide gels and then
transferred to Immobilon-P transfer membranes (Mandel, Guelph,
Canada) overnight at 41C in the presence of a blocking buffer
containing 5% milk powder. The membranes were incubated for
2h with one of the three different primary antibodies (clones 28
and 48 and 2F1) diluted 1:2000 in 1% milk powder buffer, washed
and then further incubated for 1h with the appropriate HRP-
conjugated secondary antibody at a dilution of 1:2000 in 1% milk
powder buffer. GAPDH was selected as the housekeeper protein to
control for loading. Finally, proteins were detected using enhanced
chemiluminescence (ECL, Amersham Pharmacia Biotech, Little
Chalfont, England) and visualised after exposure to a Kodak
autoradiography film. Scanning densitometry was performed to
quantitate band intensities by volume/area integration (Molecular
Dynamics, Sunnyvale, CA, USA).
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sM30-Apoptosense
TM Elisa
The M30-Apoptosenset Elisa assay is a commercially available kit
based on a 96-well plate format and was operated according to the
manufacturer’s instructions. In brief, 25ml of sample (standard,
blank, QC, or culture medium) was added to each well, which was
coated with a mouse monoclonal catcher antibody that binds to an
epitope on CK18 (M6 antibody). Simultaneously, 75ml of HRP-
conjugated monoclonal antibody (M30) solution was added to act
as the detecting antibody by binding to the caspase cleavage site
(neo-epitope (NE)) at the N-terminus of the Asp
396 fragment of
CK18 (Leers et al, 1999). Samples were then incubated for 4h at
room temperature with constant shaking, after which excess
unbound conjugate was removed by addition of the wash solution,
times five. Colour development was achieved by the addition of
200ml of 3,30,5,50-tetramethyl-benzidine solution, followed by an
incubation for 20min in the dark. The reaction was stopped by the
addition of 50ml of 1.0 M sulphuric acid and absorbance was finally
measured in a microplate reader at 450nm. By plotting a standard
curve of known concentrations of M30 antigen vs absorbance, the
amount of antigen in the QCs and unknown samples was
calculated by interpolation.
RESULTS AND DISCUSSION
Three different methodologies have been selected for validation,
each of which will be employed as a PD assay during a phase I trial
to assess the efficacy of an antisense oligonucleotide AEG 35156/
GEM 640 targeting the inhibitor of apoptosis protein XIAP.
Current CR-UK policy regarding laboratory investigations that
support clinical trials requires that a greater degree of method
validation is performed depending on the order of priority
designated to the PD assay (CR-UK policy document, 2001).
These standards are likely to become even more exacting with the
introduction of the EU directive on clinical trials 2001/20/EU
(Fontaine and Rosengren, 2001) as a legal requirement in the UK
(Statutory Instrument 1031, HMSO) from 1 May 2004. Since
traditional end points such as bone marrow toxicity, developed for
phase I evaluation of the toxicity of nonselective DNA-damaging
cytotoxic drugs, may be less relevant to the newer molecular
targeted therapies such as antisense, greater emphasis is now
placed on measurement of biological responses (i.e. PD assays) as
potential trial end points (Workman, 2003). However, many of the
PD methods that measure putative changes in the expression of
macromolecular drug targets are by their nature semiquantitative,
and internationally accepted guidelines for the validation of such
assays are less clear (Shah et al, 2000; Miller et al, 2001).
In the context of the present work, qRT-PCR was designated as
the PD assay of primary importance, with the Western blotting
technique being secondary to it. The M30-Apoptosenset plasma
Elisa is a surrogate assay for apoptosis occurring in the tumour
(Biven et al, 2003; Ueno et al, 2003), which by itself is only
potentially a secondary effect of antisense treatment, and was
therefore considered a tertiary assay.
qRT-PCR of XIAP mRNA in QC cell lines pellets
As a consequence of qRT-PCR being designated as the primary PD
assay, the validation plan focused on several key elements:
incorporation of an XIAP standard for calibration and determina-
tion of dynamic range; confirmation of the specificity of the
commercially available PCR primers and Taqman probe for XIAP;
identification of two internal control housekeeping genes and use
of both high and low XIAP as QC samples.
A plasmid (pCI) containing human cDNA to XIAP was
investigated as the standard and Figure 1 illustrates that the assay
was linear (mean regression correlation coefficient (r
2) value of
0.99970.001 standard deviation (s.d., n¼6) over a dynamic range
of four orders of magnitude of DNA concentration. Limit of
detection was defined as 0.00012pg cDNA equivalents or a CT
value of 38. However, it was observed that in blank no template
control wells a significant CT value of 35 or above was occasionally
recorded, which was eliminated in the absence of the cDNA
calibration curve. It was concluded that the presence of high
concentrations of cDNA on the plate was responsible for cross-
contamination, and all subsequent validation experiments were
based solely on the analysis of the precision of the QC samples.
Thus, the plasmid XIAP standard was used only to establish the
dynamic range of the assay. The lack of the calibration curve would
define the assay as semiquantitative (Miller et al, 2001). Never-
theless, due to the inherent robustness of qRT-PCR as a
quantitative technique, workers have suggested that comparable
results can be obtained without the need for a calibration curve
(Peirson et al, 2003).
The specificity of the commercially available Taqman probe and
PCR primers for XIAP was confirmed in a series of preliminary
experiments (data not shown) summarised as follows: a single and
correct-sized amplicon was visualised on an acrylamide gel; the
assay did not amplify mouse or rat XIAP orthologs; the signal was
not destroyed by DNAse prior to the RT step, but was destroyed
post RT step; the signal was eliminated by RNAse treatment prior
to RT step but not post RT step and no signal was detected in no
template controls.
A total of five different genes were investigated in order to
identify two of them as internal control housekeepers: GADPH,
cyclophilin A, beta 2 microglobulin, 18S rRNA and Tata-binding
protein. GAPDH produced an almost parallel response to XIAP in
the high-QC cell line, when different amounts of RNA were
assayed, with a comparison of slope values equal to 0.0302, where 0
reflects a perfect match and 1 represents no correspondence. Of
the other four genes, only beta 2 microglobulin achieved an
acceptable parallel response (comparison of slopes¼0.378). These
two genes were taken forward as the two housekeepers in a series
of precision experiments performed with the high and low XIAP
expression QCs (see Table 1 for within-day and Table 2 for
between-day). Either utilising the two housekeeper genes for delta
CT measurements or the CT value of XIAP on its own, precision
was always less than 5%, representing almost one order of
magnitude less variability than normally expected in a PD assay of
a macromolecule (Miller et al, 2001), but in line with recent
validation reports for qRT-PCR methods the determination of
transcripts of the Wilms tumour suppressor gene (WT1) (Dumur
et al, 2002) and the bcr–abl oncogene (Jones et al, 2003).
Stability of XIAP mRNA was determined by sequential analysis
of triplicate cell pellets of the two different control cell lines (low
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Figure 1 Dynamic range of a qRT-PCR method for XIAP evaluated
using a purified pCI plasmid containing full-length human XIAP cDNA as
the template.
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sand high XIAP expressers) over a period of 106 days. While values
for XIAP mRNA determined by qRT-PCR fluctuated by as much as
10% both in an upwards and downwards direction, by day 106 of
the incubation there was no significant difference in delta CT
compared to time zero (Figure 2).
Many may consider immunohistochemistry (IHC) as the ideal
primary PD assay technique to detect protein KD and thus evaluate
an antisense therapy, rather than qRT-PCR. IHC has been applied
in numerous previous reports in the analysis of XIAP expression in
human tumours (Tamm et al, 2000; Ferreira et al, 2001; Bilim et al,
2003; Kashkar et al, 2003; Krajewska et al, 2003). However, almost
without exception in these studies, the specificity of the technique
was not evaluated using an XIAP-deficient or null matrix, such as
the low QC used in the present study, the X-G4 clone stably
transfected with a vector containing an siRNA to XIAP. In
addition, it is clear that IHC – at best – yields only a three- to four-
fold dynamic range of staining intensity (Bilim et al, 2003; Kashkar
et al, 2003; Krajewska et al, 2003), which is unlikely to conclusively
detect a modest level of KD (30–40%) that may nevertheless be
sufficient to tip the balance between anti- and proapoptotic
signalling in favour of cell death. The increased dynamic range,
high sensitivity, consistency and robustness of the qRT-PCR assay
reported in this paper were therefore given preference to the
obvious benefit of IHC of being to visualise between tumour and
nontumour cells in biopsies. This decision was strengthened by the
fact that the majority of samples that will be collected during the
phase I trial of AEG 35156/GEM 640 will be surrogate nontumour
tissues, where the advantage of IHC is not relevant. While issues of
dynamic range and consistency of staining may not be insur-
mountable obstacles to validating IHC, it is the specificity of the
technique that raises most concern. Indeed, with the advantage of
tissue from genetically engineered XIAP-deficient mice, we have
observed significant staining, and therefore a lack of specificity,
with a number of commercially available antibodies and with
multiple staining protocols (unpublished observations).
Western blot analysis of XIAP in QC cell line pellets
WBA has been employed to characterise the effect of antisense
treatment on the expression levels of a number of antiapoptotic
proteins, including Bcl-2 and Bcl-xL as well as XIAP (Jansen et al,
2000; Hayward et al, 2003; Hu et al, 2003). From the perspective of
validation, two essential resources are required before a method
can be judged as quantitative: (1) a purified standard of the protein
of interest (XIAP) homologous to that of the endogenous protein
and (2) a supply of blank control matrix similar to that of the
patient samples, but minus the protein of interest (Miller et al,
2001). In the present study, an XIAP–GST fusion protein was used
as the protein standard to yield XIAP concentrations in protein
equivalents. This standard was added to 10mg of protein extract
prepared from X-G4 cells stably expressing an RNAi with virtually
undetectable XIAP protein to act as a surrogate matrix. In
addition, XIAP protein levels were quantitated as a ratio to
GAPDH, used as housekeeping protein to control for equal protein
loading. The validation strategy concentrated on evaluating
specificity, dynamic range, reproducibility and sample stability.
The main model to test the specificity of the antibody and the
Western blotting technique was the XIAP-deficient cell line clone
X-G4 (McManus et al, 2004). In addition, the presence of a single
band corresponding to the molecular weight of the protein at
55kDa in the parental cell line (U6-E1) was an absolute
requirement, as well as an equivalent band in the two QC cell
lines (HeLa and SF268). Of the three antibodies studied (see
Materials and Methods), clone 28 produced the best results,
satisfying the criteria set above, and was adopted for all future
validation experiments (see lanes 11–13 in Figure 3).
The assay was demonstrated to exhibit a 29-fold linear dynamic
range in protein concentration from 2.8 to 80pg GST–XIAP per mg
matrix (Figure 3), with an average r
2 value of 0.99870.001 s.d.,
n¼7. By interpolation, the low QC cell lines contained (approxi-
mately, see below for precision) 10pg GST–XIAP equivalents per
mg protein and the high QC contained (approximately, see below
for precision) 30pg GST–XIAP equivalents per mg protein
(Figure 3).
Within-day and between-day precision data are presented for
the low- and high-QC samples in Tables 3 and 4, respectively, and
ranged from 9.1 to 12.8% for within-day and from 22.8 to 33.5%
for between-day, even when normalised to GADPH. However,
these values are in keeping with the expected norm for Western
blot analysis (Miller et al, 2001). Figure 4 shows a typical Western
blot analysis of peripheral blood mononuclear cells isolated from a
Table 1 Within-day precision in the measurement of XIAP by real-time
RT–PCR in QC samples
Delta CT CT XIAP
Eight replicates in 1 day Average CV (%) Average CV (%)
GAPDH
U6-E1 (high QC) 7.3 2.27 28.36 0.34
X-G4 (low QC) 10.1 1.75 31.23 0.58
B2M
U6-E1 (high QC) 4.8 4.23 28.26 0.48
X-G4 (low QC) 7.85 3.2 31.22 0.59
Table 2 Between-day precision in the measurement of XIAP by real-
time RT–PCR in QC samples
Delta CT CT XIAP
Five separate days of three replicates Average CV% Average CV%
GAPDH
U6-E1 (high QC) 7.36 4.32 28.20 0.40
X-G4 (low QC) 10.3 3.48 31.18 0.37
B2M
U6-E1 (high QC) 4.68 7.3 28.42 0.72
X-G4 (low QC) 7.84 4.28 31.47 0.79
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Figure 2 Stability of XIAP mRNA determined by qRT-PCR in replicate
pellets of the high and low XIAP expression QC cell lines stored at  801C
over 106 days. At the time intervals indicated, three replicates were
removed from the freezer and analysed. Each time point represents the
mean7s.d. Results are expressed relative to GAPDH as delta CT values.
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shealthy volunteer, analysed at four different protein-loading levels,
together with GADPH as the housekeeper gene.
Stability of XIAP protein was determined by sequential analysis
of triplicate cell pellets of the two different control cell lines (low
and high XIAP expressers) over a period of 60 days. Results
showed that no significant changes in XIAP protein equivalents
(Figure 5) or XIAP/GAPDH ratios occurred.
Detection of caspase-cleaved CK18 (CK-ASP
396 NE) in QC
samples by the M30-Apoptosenset Elisa assay
Each M30-Apoptosenset kit includes a five-point calibration curve
(including a blank) extending over an antigen concentration range
of 50–1000Ul
 1 and high- and low-QC samples of certified
antigen concentration (circa 750 and 100Ul
 1). The focus of the
validation plan was to generate independent positive and negative
QC samples, in order to perform a more extensive evaluation of
precision, conduct kit-to-kit QC and follow the stability of the
antigen when stored at  801C and exposed to 371C. Independent
QCs were generated by incubation of MDA-MB-231/X-G4 cells
with 100nM staurosporine for 48h. After centrifugation, media
were assayed to determine the level of antigen. Finally, media were
pooled, diluted appropriately and individually aliquoted (150
positive and 100 negative aliquots) to yield a positive independent
control with an antigen value of (circa) 600Ul
 1. The aliquots of
conditioned media were stored at  801C.
In a separate study to confirm that the appearance of M30
antigen in the culture media was due to the induction of apoptosis,
MDA-MB-231/X-G4 cells were treated with 10 or 100nM staur-
osporine for 24h in the presence or absence of the broad-spectrum
caspase inhibitor z-VAD. Figure 6 shows that a 10-fold increase in
concentration of staurosporine resulted in a four-fold increase in
M30 antigen. The addition of 50mM z-VAD completely abolished
the release of cleaved CK18 into media, both in the case of 10 and
100nM staurosporine.
Using a series of nine different dilutions of the positive control,
the calibration curve for the Elisa assay was demonstrated to follow
the classic shape of a sigmoid plot with a value of r
2 equalling
0.997, and a plateau occurring at antigen concentrations of
1000Ul
 1 and above, the upper limit of the calibration curve
supplied by the manufacturers. Typical within-day precision using
eight replicates was 3.6% for the independent positive control and
6.7% for the negative control. Analyses performed on eight
separate days over a 3-month period yielded a mean value of
620Ul
 1 for the positive control, with a between-day precision of
2.4%. Kit-to-kit variations in the concentration of antigen
determined in the positive control was 3.7% between kits 1 and
2, 4.8% between kits 2 and 3, and 1.5% between kits 3 and 4, well
GAPDH 
XIAP 
GST−XIAP 
1 2  3  4  5  6  7  8  9  10  11  12  13
Figure 3 Calibration of a Western blotting technique for the
determination of XIAP using a GST–XIAP protein standard. The fusion
protein diluted in MDA-MB-231/X-G4 lysate was analysed within a
concentration range of 0.06–135pgmg
 1. Lanes are identified as follows:
GST–XIAP (pgmg
 1) at 135, lane 1; 110, lane 2; 80, lane 3; 55, lane 4; 28,
lane 5; 5.5, lane 6; 2.8, lane 7; 0.55, lane 8; 0.28, lane 9 and 0.06, lane 10.
Also included on the blot are the XIAP-deficient cell line MDA-MB-231/X-
G4, lane 11; the low QC cell line SF268, lane 12 and the high-QC cell line
HeLa, lane 13. The blot was also probed for GAPDH, which acted as a
housekeeper protein.
Table 3 Within-day precision in the measurement of XIAP by Western
blot analysis in QC samples
Eight replicates
XIAP/GAPDH ratio XIAP minus background
Mean value
(pg per lg
total protein)
Precision
(CV%)
Mean value
(pg per lg
total protein)
Precision
(CV%)
SF268 (low QC) 10.3 11.2 12.3 9.1
HeLa (high QC) 28.1 12.8 28.9 11.0
Table 4 Between-day precision in the measurement of XIAP by
Western blot analysis in QC samples
Five different
days, three
replicates
XIAP/GAPDH ratio XIAP minus background
Mean value
(pg per lg
total protein)
Precision
(CV%)
Mean value
(pg lg total
protein)
Precision
(CV%)
SF268 (low QC) 8.0 28.7 8.6 33.5
HeLa (high QC) 30.1 22.8 34.1 23.6
XIAP 
GAPDH 
1            2              3               4
Figure 4 Western blot analysis of XIAP in peripheral blood mono-
nuclear cells harvested from a healthy volunteer. Each lane was assayed at a
different level of total protein loading. Lanes are identified as follows: 1,
5mg; 2, 10mg; 3, 20mg and 4, 40mg. The blot was also probed for GAPDH,
which acted as a housekeeper protein.
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Figure 5 Stability of XIAP protein determined by Western blot in
replicate pellets of the high and low XIAP expression QC cell lines stored
at  801C over 60 days. At the time intervals indicated, three replicates
were removed from the freezer and analysed. Each time point represents
the mean7s.d.
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swithin the manufacturer’s acceptance criteria of 10% (http://
web.peviva.se/index.asp). The stability of the positive control QC
samples when stored at  801C was followed over a 6-month period
(Figure 7). Values remained stable for 3 months, after which time
there was a gradual and persistent increase from the plateau value
of 620–716Ul
 1, representing a 15.5% drift in concentration. The
manufacturers recommend that plasma samples are stable for at
least 6 months when stored at  801C due to the robustness of the
M30 antigen (Carr, 2000). In our studies, the QC samples consisted
of RPMI media containing 10% serum and this may account for
the difference. The M30 antigen (CK18-ASP
396 NE) was relatively
stable in volunteer plasma incubated at 371C in the dark with a
half-life of between 80 and 100h (Figure 8).
M30 is a monoclonal antibody that recognises an NE mapped to
positions 387–396, of a caspase-cleaved fragment of CK18, with a
liberated C-terminus at the cleavage site of DALD-S (Leers et al,
1999). The antibody has been validated in the format of IHC for
several years as a marker of apoptosis (marketed as M30
CytoDeath, Roche, Basel, Switzerland), and has been shown to be
more robust than TUNEL and ISEL (Carr, 2000). It has been
applied successfully in a number of patient studies to measure
apoptosis (Kusama et al, 2000; Kadyrov et al, 2001; Leers et al,
2002; Mirzaie-Joniani et al, 2002; Rupa et al, 2003). More recently,
the M30 antibody has been employed in the format of an Elisa
assay for in vitro high throughput screening of apoptosis-inducing
compounds against cancer cell lines and for the analysis of serum
or plasma from patients as a surrogate marker for tumour cell
apoptosis (Biven et al, 2003; Ueno et al, 2003). In this format, the
assay relies on the fact that apoptotic cells release cleaved CK18
into the culture medium or circulation of patients. Since CK18 is
believed to be expressed only in cells of epithelial origin,
theoretically the assay should not be subjected to interference by
bone marrow cell death.
In summary, validation strategies and data are presented on the
performance of three PD assays commonly used in early clinical
trials of new anticancer drugs using cancer cell pellets as a
surrogate tissue for patient tumour biopsies. Although these assays
are tailored for the analysis of an antisense therapy targeting XIAP,
it is hoped that the general principles of method validation
presented may have broader applicability to other new agents
requiring PD end point assays during early-phase clinical
evaluation.
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